IFN-γ Signature Enables Selection of Neoadjuvant Treatment in Patients with Stage III Melanoma

Patients with stage III melanoma and high intra-tumoral interferon-γ (IFN-γ) scores were randomized to neoadjuvant nivolumab or nivolumab + domatinostat, while patients with low IFN-γ scores received nivolumab + domatinostat or ipilimumab + nivolumab + domatinostat.